Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Depreciation & Amortization (CF) (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 11.12% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, down 12.77% year-over-year, with the annual reading at $4.1 million for FY2025, 12.77% down from the prior year.
  • Depreciation & Amortization (CF) hit $1.1 million in Q4 2025 for Voyager Therapeutics, up from $932000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.8 million in Q1 2022 to a low of $843000.0 in Q4 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $1.2 million across 5 years, with a median of $1.2 million in 2021.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 120.72% in 2022 and later tumbled 61.77% in 2023.
  • Year by year, Depreciation & Amortization (CF) stood at $1.5 million in 2021, then crashed by 44.43% to $843000.0 in 2022, then surged by 53.5% to $1.3 million in 2023, then decreased by 24.27% to $980000.0 in 2024, then rose by 11.12% to $1.1 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for VYGR at $1.1 million in Q4 2025, $932000.0 in Q3 2025, and $1.1 million in Q2 2025.